E!5726, nuflo CelTx, Cellcolabs AB
| Reference number | |
| Coordinator | Cellcolabs AB |
| Funding from Vinnova | SEK 3 500 000 |
| Project duration | July 2024 - July 2026 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
The nuflo CelTx project is developing a treatment for critical limb ischemia (CLI). By combining electrospun membranes, stent-based carriers, and mesenchymal stem cells (MSCs), the nuflo CelTx project aims to create a natural bypass to improve blood flow and tissue perfusion. Within the project, Cellcolabs aims to develop and produce GMP-grade adipose MSCs, focusing on generating pro-angiogenic cells from both bone marrow and adipose tissue.
Expected effects and result
The expected effects and results for Cellcolabs in the nuflo CelTx project include the development of GMP-quality mesenchymal stem cells (MSCs) with proangiogenic properties, which are integrated into an organoid-like nanofiber membrane to create a natural bypass and improve blood flow in CLI patients.
Planned approach and implementation
Cellcolabs will develop GMP-quality MSCs from bone marrow and adipose tissue by establishing manufacturing protocols and ensuring the proangiogenic properties of the cells. They will load cells onto electrospun membranes, test cell viability and functionality, and develop preservation protocols for long-term storage. The goal is to create a clinically viable product.